溶解性尿酶类型等离子体激活受体 (suPAR) 和急性肺栓塞的死亡率
Crhistian-Mario Oblitas1, Marina López-Rubio1, Marta-Olimpia Lago-Rodríguez1
1Venous Thromboembolism Unit, Internal Medicine Department, General University Hospital Gregorio Marañón, Madrid, Spain; School of Medicine, University Complutense of Madrid, Spain; Sanitary Research Institute Gregorio Marañón, Madrid, Spain.
概括
可溶性尿素激酶类型等离子体激活受体 (suPAR) 显示为预测肺栓塞 (PE) 患者短期死亡率的生物标志物具有前景. 较高的suPAR水平与30天死亡风险的增加有关.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 心血管医学 心血管医学
背景情况:
- 可溶性尿素激酶类型等离子体激活受体 (suPAR) 与免疫血栓形成有关,但其在肺栓塞 (PE) 中的预后作用尚不清楚.
- 在复杂的疾病背景下,suPAR对等离子体活性和化学反应的潜在影响仍然不太清楚.
研究的目的:
- 评估suPAR水平对被诊断患有急性症状PE的患者短期死亡的预后能力.
- 评估suPAR作为PE患者风险分层的潜在生物标志物.
主要方法:
- 对已确认急性症状PE的连续成年患者进行前性,观察性,单中心研究.
- 在诊断时测量了suPAR水平;30天死亡率是主要终点.
- 进行了接收器操作特征 (ROC) 曲线分析和生存分析.
主要成果:
- 该研究包括52名患者 (平均年龄为73.8岁);13.5%的患者在30天内死亡.
- 5.5 ng/mL的suPAR切线预测死亡率,曲线下的面积 (AUC) 为0.72.
- 升高的suPAR (>5.5 ng/mL) 与30天死亡率的增加显著相关 (OR 10,HR 8.33).
结论:
- suPAR是预测急性症状PE患者短期死亡率的潜在生物标志物.
- suPAR水平可能有助于提高PE患者的风险分层,指导临床管理.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
166
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
166
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
152
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
152


